Hwi-yeol Yun

List of Publications by Year
in descending order

71 papers	714 citations	623734 14 h-index	642732 23 g-index
72 all docs	72 docs citations	72 times ranked	1100 citing authors

#	Article	IF	Citations
1	Bioanalysis of lanreotide in dog plasma using liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of beagle dogs after single subcutaneous injection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1188, 123078.	2.3	1
2	Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. Pharmaceutics, 2022, 14, 244.	4.5	4
3	Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis. Open Forum Infectious Diseases, 2022, 9, ofab660.	0.9	6
4	A simple time-to-event model with NONMEM featuring right-censoring. Translational and Clinical Pharmacology, 2022, 30, 75.	0.9	0
5	The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. Pharmaceutics, 2022, 14, 1446.	4.5	2
6	Dose Optimization of Vancomycin Using a Mechanism-based Exposure–Response Model in Pediatric Infectious Disease Patients. Clinical Therapeutics, 2021, 43, 185-194.e16.	2.5	4
7	Molecular design of anticancer drugs from marine fungi derivatives. RSC Advances, 2021, 11, 20173-20179.	3.6	9
8	Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data. Pharmaceuticals, 2021, 14, 114.	3.8	1
9	External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. British Journal of Clinical Pharmacology, 2021, 87, 3878-3889.	2.4	4
10	Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index. Risk Management and Healthcare Policy, 2021, Volume 14, 1855-1867.	2.5	1
11	Compatibility Study between Physiologically Based Pharmacokinetic (PBPK) and Compartmental PK Model Using Lumping Method: Application to the Voriconazole Case. Korean Journal of Clinical Pharmacy, 2021, 31, 125-135.	0.3	0
12	Prediction of fluoxetine and norfluoxetine pharmacokinetic profiles using physiologically based pharmacokinetic modeling. Journal of Clinical Pharmacology, 2021, 61, 1505-1513.	2.0	0
13	Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models. Pharmaceuticals, 2021, 14, 654.	3.8	1
14	Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 106-112.	4.3	0
15	Analysis of Pembrolizumab-induced Blood Glucose Level Change in Cancer Patients. Korean Journal of Clinical Pharmacy, 2021, 31, 237-246.	0.3	0
16	Model-Based Prediction to Evaluate Residence Time of Hyaluronic Acid Based Dermal Fillers. Pharmaceutics, 2021, 13, 133.	4.5	6
17	Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice. Frontiers in Pharmacology, 2021, 12, 793349.	3.5	2
18	Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor–Mediated Recycling of HL2351, a Novel Hybrid Fc–Fused Interleukin–1 Receptor Antagonist, to Optimize Dosage Regimen. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 584-595.	2.5	4

#	Article	IF	Citations
19	Clinical Evaluation of Acetaminophenâ€"Galgeuntang Interaction Based on Population Approaches. Pharmaceutics, 2020, 12, 1182.	4.5	3
20	Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics, 2020, 12, 1040.	4.5	4
21	Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans. International Journal of Molecular Sciences, 2020, 21, 1862.	4.1	2
22	Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections . Risk Management and Healthcare Policy, 2020, Volume 13, 685-695.	2.5	2
23	Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor. Pharmaceutical Research, 2020, 37, 44.	3.5	4
24	Beyond the Michaelisâ€Menten: Accurate Prediction of $In Vivo$ Hepatic Clearance for Drugs With Low K_M. Clinical and Translational Science, 2020, 13, 1199-1207.	3.1	6
25	Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients. Pharmaceutics, 2020, 12, 336.	4.5	0
26	Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients. Scientific Reports, 2019, 9, 11740.	3.3	5
27	Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients. Pharmaceutics, 2019, 11, 259.	4.5	19
28	Economic Impact of Pharmacist-Participated Medication Management for Elderly Patients in Nursing Homes: A Systematic Review. International Journal of Environmental Research and Public Health, 2019, 16, 2955.	2.6	7
29	Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. Scientific Reports, 2018, 8, 1687.	3.3	21
30	Prediction of Methionine and Homocysteine levels in Zucker diabetic fatty (ZDF) rats as a T2DM animal model after consumption of a Methionine-rich diet. Nutrition and Metabolism, 2018, 15, 14.	3.0	7
31	External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2018, 84, 153-171.	2.4	45
32	Dose Optimization Based on Population Pharmacokinetic Modeling of High-Dose Cyclosporine, a P-glycoprotein Inhibitor, in Combination with Systemic Chemotherapy in Pediatric Patients with Retinoblastoma. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 647-655.	1.4	3
33	A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption. BMC Pharmacology & Toxicology, 2018, 19, 4.	2.4	9
34	Age-Related Changes in Sulfur Amino Acid Metabolism in Male C57BL/6 Mice. Biomolecules and Therapeutics, 2018, 26, 167-174.	2.4	10
35	Population Pharmacokinetic Modeling and Simulation of Afloqualone to Predict Steady-state Exposure Levels. International Journal of Pharmacology, 2018, 14, 276-284.	0.3	0
36	Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 38-42.	4.3	61

#	Article	IF	Citations
37	Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 677-687.	2.5	28
38	Development of a LC–MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 123-127.	2.3	0
39	Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects. BMC Medical Research Methodology, 2017, 17, 154.	3.1	5
40	Hormone Therapy Review for Perimenopausal Symptoms: Focused on Perimenopausal Women without Other Risk Factors. Korean Journal of Clinical Pharmacy, 2017, 27, 199-206.	0.3	0
41	Influence of Oxygen to Population Pharmacokinetics/Pharmacodynamics of Alcohol in Healthy Volunteers. Korean Journal of Clinical Pharmacy, 2017, 27, 258-266.	0.3	0
42	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. Cancer Chemotherapy and Pharmacology, 2016, 78, 623-632.	2.3	9
43	Determination of Matrine in Rat Plasma after Oral Administration of Novel Korean Herbal Medicine KIOM-MA128 and Application of PK. Journal of Analytical Methods in Chemistry, 2015, 2015, 1-6.	1.6	1
44	Development of QTc prolongation model incorporating circadian rhythm using harmonic model. Xenobiotica, 2015, 45, 420-427.	1.1	1
45	A novel HPLC–MS/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 121-126.	2.8	3
46	Population Pharmacokinetics of Cyclosporine in Hematopoietic Stem Cell Transplant Patients. Annals of Pharmacotherapy, 2015, 49, 622-630.	1.9	11
47	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis, 2015, 95, 54-59.	1.9	27
48	Absolute bioavailability and metabolism of aceclofenac in rats. Archives of Pharmacal Research, 2015, 38, 68-72.	6.3	13
49	Quantitative determination of amisulpride in rat plasma by HPLC–MS/MS. Archives of Pharmacal Research, 2015, 38, 63-67.	6.3	12
50	Semi–Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Antiplatelet Agents. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 352-359.	2.5	7
51	A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. Drug Development and Industrial Pharmacy, 2014, 40, 1325-1329.	2.0	10
52	Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. European Journal of Clinical Pharmacology, 2014, 70, 1211-1219.	1.9	22
53	Population Pharmacokinetic–Pharmacogenetic Model of Tacrolimus in the Early Period after Kidney Transplantation. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 400-406.	2.5	43
54	A Population Pharmacokinetic Analysis of the Influence of Nutritional Status of Digoxin in Hospitalized Korean Patients. Clinical Therapeutics, 2014, 36, 389-400.	2.5	5

#	Article	IF	Citations
55	Simultaneous determination of 7-O-succinyl macrolactin A and its metabolite macrolactin A in rat plasma using liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 85-89.	2.8	11
56	Development of a population pharmacokinetic model to describe olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 676-683.	0.6	4
57	Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. European Journal of Clinical Pharmacology, 2013, 69, 1543-1551.	1.9	20
58	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. European Journal of Clinical Pharmacology, 2013, 69, 53-63.	1.9	62
59	Simultaneous Determination of Olanzapine and its Major Metabolite N-Desmethyl Olanzapine in Rat Plasma by HPLC-MS/MS: Application of PK in Rat. Bulletin of the Korean Chemical Society, 2013, 34, 2567-2568.	1.9	0
60	CYP3A5 Polymorphism Effect on Cyclosporine Pharmacokinetics in Living Donor Renal Transplant Recipients: Analysis by Population Pharmacokinetics. Annals of Pharmacotherapy, 2012, 46, 1141-1151.	1.9	13
61	ABCB1 C3435T Genetic Polymorphism on Population Pharmacokinetics of Methotrexate After Hematopoietic Stem Cell Transplantation in Korean Patients: A Prospective Analysis. Clinical Therapeutics, 2012, 34, 1816-1826.	2.5	31
62	A Phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1471-1479.	3.3	4
63	Population Pharmacokinetics of Cyclosporine in Korean Adults Undergoing Living-Donor Kidney Transplantation. Pharmacotherapy, 2011, 31, 574-584.	2.6	6
64	Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Archives of Pharmacal Research, 2008, 31, 814-821.	6.3	16
65	Effects of smoking on the pharmacokinetics and pharmacodynamics of a nicotine patch. Biopharmaceutics and Drug Disposition, 2008, 29, 521-528.	1.9	10
66	Facile Synthesis of Trisaccharide Moiety Corresponding to Antitumor Activity in Triterpenoid Saponins Isolated from Pullsatilla Roots. Chemical and Pharmaceutical Bulletin, 2007, 55, 1734-1739.	1.3	8
67	Simultaneous analysis of naltrexone and its major metabolite, 6-β-naltrexol, in human plasma using liquid chromatography–tandem mass spectrometry: Application to a parent-metabolite kinetic model in humans. Talanta, 2007, 71, 1553-1559.	5.5	13
68	Determination of afloqualone in human plasma using liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic studies in humans. Talanta, 2007, 73, 635-643.	5.5	6
69	The Effects of Food on the Bioavailability of Fenofibrate Administered Orally in Healthy Volunteers via Sustained-Release Capsule. Clinical Pharmacokinetics, 2006, 45, 425-432.	3.5	22
70	Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. European Journal of Clinical Pharmacology, 2006, 62, 1033-1039.	1.9	17
71	Determination of benidipine in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 311-314.	2.3	20